Theravance Biopharma, Inc. 8-K

What Happened

• On March 19, 2026, Theravance Biopharma, Inc. announced its financial results for the quarter and full year ended December 31, 2025 and issued a business update. The company furnished a press release with those results as Exhibit 99.1 to the Current Report on Form 8-K.

Key Details

• Item reported: 2.02 (Results of Operations and Financial Condition) — Theravance reported quarterly and full‑year results for the period ending Dec. 31, 2025.
• Press release furnished as Exhibit 99.1 to the 8‑K on March 19, 2026.
• The exhibit/information is furnished, not “filed,” and therefore is not subject to the liabilities of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8‑K signals that Theravance released its latest earnings/quarterly results and a business update; investors should read the furnished press release (Exhibit 99.1) for specifics on revenue, net income/loss, guidance, pipeline or operational changes. Because the release is furnished rather than filed, it has different legal implications but still contains material operational and financial information that could affect the stock.